Inhaled nitric oxide to treat intermediate risk pulmonary embolism: A multicenter randomized controlled trial

Jeffrey A. Kline, Michael A. Puskarich, Alan E. Jones, Ronald A. Mastouri, Cassandra L. Hall, Anthony Perkins, Emily E Gundert, Tim Lahm

Research output: Contribution to journalArticle

Abstract

Objective: To test the hypothesis that adjunctive inhaled NO would improve RV function and viability in acute PE. Methods: This was a randomized, placebo-controlled, double blind trial conducted at four academic hospitals. Eligible patients had acute PE without systemic arterial hypotension but had RV dysfunction and a treatment plan of standard anticoagulation. Subjects received either oxygen plus 50 parts per million nitrogen (placebo) or oxygen plus 50 ppm NO for 24 h. The primary composite endpoint required a normal RV on echocardiography and a plasma troponin T concentration <14 pg/mL. The secondary endpoint required a blood brain natriuretic peptide concentration <90 pg/mL and a Borg dyspnea score ≤ 2. The sample size of N = 76 tested if 30% more patients treated with NO would achieve the primary endpoint with 80% power and alpha = 5%. Results: We randomized 78 patients and after two withdrawals, 38 were treated per protocol in each group. Patients were well matched for baseline conditions. At 24 h, 5/38 (13%) of patients treated with placebo and 9/38 (24%) of patients treated with NO reached the primary endpoint (P = 0.375). The secondary endpoint was reached in 34% with placebo and 13% of the NO (P = 0.11). In a pre-planned post-hoc analysis, we examined how many patients with RV hypokinesis or dilation at enrollment resolved these abnormalities; 29% more patients treated with NO resolved both abnormalities at 24 h (P = 0.010, Cochrane's Q test). Conclusions: In patients with severe submassive PE, inhaled nitric oxide failed to increase the proportion of patients with a normal troponin and echocardiogram but increased the probability of eliminating RV hypokinesis and dilation on echocardiography. Clinical trial registration: NCT01939301.

Original languageEnglish (US)
Pages (from-to)60-68
Number of pages9
JournalNitric Oxide - Biology and Chemistry
Volume84
DOIs
StatePublished - Mar 1 2019

Fingerprint

Echocardiography
Pulmonary Embolism
Nitric Oxide
Randomized Controlled Trials
Oxygen
Troponin T
Troponin
Brain Natriuretic Peptide
Blood
Nitrogen
Plasmas
Placebos
Composite materials
Dilatation
Dyspnea
Sample Size
Hypotension
Clinical Trials

Keywords

  • Brain natriuretic peptide
  • Echocardiography
  • Heart failure
  • Nitric oxide
  • Pulmonary embolism
  • Pulmonary hypertension
  • Randomized trial
  • Troponin

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Clinical Biochemistry
  • Cancer Research

Cite this

Kline, J. A., Puskarich, M. A., Jones, A. E., Mastouri, R. A., Hall, C. L., Perkins, A., ... Lahm, T. (2019). Inhaled nitric oxide to treat intermediate risk pulmonary embolism: A multicenter randomized controlled trial. Nitric Oxide - Biology and Chemistry, 84, 60-68. https://doi.org/10.1016/j.niox.2019.01.006

Inhaled nitric oxide to treat intermediate risk pulmonary embolism : A multicenter randomized controlled trial. / Kline, Jeffrey A.; Puskarich, Michael A.; Jones, Alan E.; Mastouri, Ronald A.; Hall, Cassandra L.; Perkins, Anthony; Gundert, Emily E; Lahm, Tim.

In: Nitric Oxide - Biology and Chemistry, Vol. 84, 01.03.2019, p. 60-68.

Research output: Contribution to journalArticle

Kline, Jeffrey A. ; Puskarich, Michael A. ; Jones, Alan E. ; Mastouri, Ronald A. ; Hall, Cassandra L. ; Perkins, Anthony ; Gundert, Emily E ; Lahm, Tim. / Inhaled nitric oxide to treat intermediate risk pulmonary embolism : A multicenter randomized controlled trial. In: Nitric Oxide - Biology and Chemistry. 2019 ; Vol. 84. pp. 60-68.
@article{537f39b9554e4d1788dbcd584b1a71fd,
title = "Inhaled nitric oxide to treat intermediate risk pulmonary embolism: A multicenter randomized controlled trial",
abstract = "Objective: To test the hypothesis that adjunctive inhaled NO would improve RV function and viability in acute PE. Methods: This was a randomized, placebo-controlled, double blind trial conducted at four academic hospitals. Eligible patients had acute PE without systemic arterial hypotension but had RV dysfunction and a treatment plan of standard anticoagulation. Subjects received either oxygen plus 50 parts per million nitrogen (placebo) or oxygen plus 50 ppm NO for 24 h. The primary composite endpoint required a normal RV on echocardiography and a plasma troponin T concentration <14 pg/mL. The secondary endpoint required a blood brain natriuretic peptide concentration <90 pg/mL and a Borg dyspnea score ≤ 2. The sample size of N = 76 tested if 30{\%} more patients treated with NO would achieve the primary endpoint with 80{\%} power and alpha = 5{\%}. Results: We randomized 78 patients and after two withdrawals, 38 were treated per protocol in each group. Patients were well matched for baseline conditions. At 24 h, 5/38 (13{\%}) of patients treated with placebo and 9/38 (24{\%}) of patients treated with NO reached the primary endpoint (P = 0.375). The secondary endpoint was reached in 34{\%} with placebo and 13{\%} of the NO (P = 0.11). In a pre-planned post-hoc analysis, we examined how many patients with RV hypokinesis or dilation at enrollment resolved these abnormalities; 29{\%} more patients treated with NO resolved both abnormalities at 24 h (P = 0.010, Cochrane's Q test). Conclusions: In patients with severe submassive PE, inhaled nitric oxide failed to increase the proportion of patients with a normal troponin and echocardiogram but increased the probability of eliminating RV hypokinesis and dilation on echocardiography. Clinical trial registration: NCT01939301.",
keywords = "Brain natriuretic peptide, Echocardiography, Heart failure, Nitric oxide, Pulmonary embolism, Pulmonary hypertension, Randomized trial, Troponin",
author = "Kline, {Jeffrey A.} and Puskarich, {Michael A.} and Jones, {Alan E.} and Mastouri, {Ronald A.} and Hall, {Cassandra L.} and Anthony Perkins and Gundert, {Emily E} and Tim Lahm",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.niox.2019.01.006",
language = "English (US)",
volume = "84",
pages = "60--68",
journal = "Nitric Oxide - Biology and Chemistry",
issn = "1089-8603",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Inhaled nitric oxide to treat intermediate risk pulmonary embolism

T2 - A multicenter randomized controlled trial

AU - Kline, Jeffrey A.

AU - Puskarich, Michael A.

AU - Jones, Alan E.

AU - Mastouri, Ronald A.

AU - Hall, Cassandra L.

AU - Perkins, Anthony

AU - Gundert, Emily E

AU - Lahm, Tim

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Objective: To test the hypothesis that adjunctive inhaled NO would improve RV function and viability in acute PE. Methods: This was a randomized, placebo-controlled, double blind trial conducted at four academic hospitals. Eligible patients had acute PE without systemic arterial hypotension but had RV dysfunction and a treatment plan of standard anticoagulation. Subjects received either oxygen plus 50 parts per million nitrogen (placebo) or oxygen plus 50 ppm NO for 24 h. The primary composite endpoint required a normal RV on echocardiography and a plasma troponin T concentration <14 pg/mL. The secondary endpoint required a blood brain natriuretic peptide concentration <90 pg/mL and a Borg dyspnea score ≤ 2. The sample size of N = 76 tested if 30% more patients treated with NO would achieve the primary endpoint with 80% power and alpha = 5%. Results: We randomized 78 patients and after two withdrawals, 38 were treated per protocol in each group. Patients were well matched for baseline conditions. At 24 h, 5/38 (13%) of patients treated with placebo and 9/38 (24%) of patients treated with NO reached the primary endpoint (P = 0.375). The secondary endpoint was reached in 34% with placebo and 13% of the NO (P = 0.11). In a pre-planned post-hoc analysis, we examined how many patients with RV hypokinesis or dilation at enrollment resolved these abnormalities; 29% more patients treated with NO resolved both abnormalities at 24 h (P = 0.010, Cochrane's Q test). Conclusions: In patients with severe submassive PE, inhaled nitric oxide failed to increase the proportion of patients with a normal troponin and echocardiogram but increased the probability of eliminating RV hypokinesis and dilation on echocardiography. Clinical trial registration: NCT01939301.

AB - Objective: To test the hypothesis that adjunctive inhaled NO would improve RV function and viability in acute PE. Methods: This was a randomized, placebo-controlled, double blind trial conducted at four academic hospitals. Eligible patients had acute PE without systemic arterial hypotension but had RV dysfunction and a treatment plan of standard anticoagulation. Subjects received either oxygen plus 50 parts per million nitrogen (placebo) or oxygen plus 50 ppm NO for 24 h. The primary composite endpoint required a normal RV on echocardiography and a plasma troponin T concentration <14 pg/mL. The secondary endpoint required a blood brain natriuretic peptide concentration <90 pg/mL and a Borg dyspnea score ≤ 2. The sample size of N = 76 tested if 30% more patients treated with NO would achieve the primary endpoint with 80% power and alpha = 5%. Results: We randomized 78 patients and after two withdrawals, 38 were treated per protocol in each group. Patients were well matched for baseline conditions. At 24 h, 5/38 (13%) of patients treated with placebo and 9/38 (24%) of patients treated with NO reached the primary endpoint (P = 0.375). The secondary endpoint was reached in 34% with placebo and 13% of the NO (P = 0.11). In a pre-planned post-hoc analysis, we examined how many patients with RV hypokinesis or dilation at enrollment resolved these abnormalities; 29% more patients treated with NO resolved both abnormalities at 24 h (P = 0.010, Cochrane's Q test). Conclusions: In patients with severe submassive PE, inhaled nitric oxide failed to increase the proportion of patients with a normal troponin and echocardiogram but increased the probability of eliminating RV hypokinesis and dilation on echocardiography. Clinical trial registration: NCT01939301.

KW - Brain natriuretic peptide

KW - Echocardiography

KW - Heart failure

KW - Nitric oxide

KW - Pulmonary embolism

KW - Pulmonary hypertension

KW - Randomized trial

KW - Troponin

UR - http://www.scopus.com/inward/record.url?scp=85060195197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060195197&partnerID=8YFLogxK

U2 - 10.1016/j.niox.2019.01.006

DO - 10.1016/j.niox.2019.01.006

M3 - Article

C2 - 30633959

AN - SCOPUS:85060195197

VL - 84

SP - 60

EP - 68

JO - Nitric Oxide - Biology and Chemistry

JF - Nitric Oxide - Biology and Chemistry

SN - 1089-8603

ER -